Lv1
70 积分 2024-04-28 加入
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
6小时前
已完结
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
8天前
已完结
Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis
10天前
已完结
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
16天前
已完结
Biocompatible Recombinant Type III Collagen Enhancing Skin Repair and Anti-Wrinkle Effects
18天前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
1个月前
已完结
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
2个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
2个月前
已完结
超声引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病对Lown分级的影响
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
皖公网安备34019202002308
